CLSD
Price:
$1.03
Market Cap:
$76.99M
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated i...[Read more]
Industry
Biotechnology
IPO Date
2016-06-02
Stock Exchange
NASDAQ
Ticker
CLSD
According to Clearside Biomedical, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 106.34M. This represents a change of 19.60% compared to the average of 88.92M of the last 4 quarters.
The mean historical Enterprise Value of Clearside Biomedical, Inc. over the last ten years is 90.07M. The current 106.34M Enterprise Value has changed 11.71% with respect to the historical average. Over the past ten years (40 quarters), CLSD's Enterprise Value was at its highest in in the September 2021 quarter at 332.39M. The Enterprise Value was at its lowest in in the March 2015 quarter at 0.
Average
90.07M
Median
88.19M
Minimum
20.46M
Maximum
175.97M
Discovering the peaks and valleys of Clearside Biomedical, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 322.34%
Maximum Annual Enterprise Value = 175.97M
Minimum Annual Increase = -84.40%
Minimum Annual Enterprise Value = 20.46M
Year | Enterprise Value | Change |
---|---|---|
2023 | 86.40M | 322.34% |
2022 | 20.46M | -84.40% |
2021 | 131.09M | 16.92% |
2020 | 112.12M | 18.63% |
2019 | 94.51M | 171.45% |
2018 | 34.82M | -80.21% |
2017 | 175.97M | 95.57% |
2016 | 89.97M | 20.48% |
2015 | 74.68M | -7.48% |
2014 | 80.72M | -7.59% |
The current Enterprise Value of Clearside Biomedical, Inc. (CLSD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
79.31M
5-year avg
88.91M
10-year avg
90.07M
Clearside Biomedical, Inc.’s Enterprise Value is less than POINT Biopharma Global Inc. (1.32B), less than ORIC Pharmaceuticals, Inc. (621.68M), greater than Lyra Therapeutics, Inc. (22.05M), greater than Inhibrx Biosciences, Inc. (411.31K), greater than ESSA Pharma Inc. (-13321596.00), greater than Sensei Biotherapeutics, Inc. (6.21M), greater than NextCure, Inc. (21.96M), less than Nuvation Bio Inc. (1.02B), greater than Graphite Bio, Inc. (-15007658.00), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Gracell Biotechnologies Inc. (5.48B), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (478.04M), less than Design Therapeutics, Inc. (258.23M), less than Erasca, Inc. (691.95M), greater than Eyenovia, Inc. (57.71M), less than Alpha Tau Medical Ltd. (163.31M), less than Ocular Therapeutix, Inc. (1.22B), less than Tenaya Therapeutics, Inc. (147.56M), less than Inozyme Pharma, Inc. (308.76M), less than Generation Bio Co. (209.62M), greater than Kronos Bio, Inc. (14.20M), less than C4 Therapeutics, Inc. (462.75M), less than Edgewise Therapeutics, Inc. (3.19B),
Company | Enterprise Value | Market cap |
---|---|---|
1.32B | $1.33B | |
621.68M | $668.74M | |
22.05M | $17.21M | |
411.31K | $225.10M | |
-13321596.00 | $72.32M | |
6.21M | $13.05M | |
21.96M | $36.65M | |
1.02B | $764.36M | |
-15007658.00 | $185.19M | |
-10189682.00 | $223.97M | |
5.48B | $989.87M | |
138.26M | $181.50M | |
478.04M | $542.54M | |
258.23M | $301.22M | |
691.95M | $810.79M | |
57.71M | $44.32M | |
163.31M | $156.63M | |
1.22B | $1.60B | |
147.56M | $190.12M | |
308.76M | $277.29M | |
209.62M | $144.16M | |
14.20M | $57.28M | |
462.75M | $455.30M | |
3.19B | $3.23B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clearside Biomedical, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Clearside Biomedical, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Clearside Biomedical, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Clearside Biomedical, Inc. (CLSD)?
What is the 3-year average Enterprise Value for Clearside Biomedical, Inc. (CLSD)?
What is the 5-year average Enterprise Value for Clearside Biomedical, Inc. (CLSD)?
How does the current Enterprise Value for Clearside Biomedical, Inc. (CLSD) compare to its historical average?